These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37947825)

  • 1. Outcomes of allogeneic hematopoietic cell transplantation under letermovir prophylaxis for cytomegalovirus infection.
    Takenaka K; Fuji S; Matsukawa T; Uchida N; Kobayashi T; Tanaka M; Ara T; Ikegame K; Ozawa Y; Kanda Y; Sawa M; Maruyama Y; Fukuda T; Nakamae H; Kimura T; Ogata M; Seo S; Atsuta Y; Matsuo K; Nakasone H
    Ann Hematol; 2024 Jan; 103(1):285-296. PubMed ID: 37947825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for late cytomegalovirus infection after completing letermovir prophylaxis.
    Mori Y; Harada T; Yoshimoto G; Shima T; Numata A; Jinnouchi F; Yamauchi T; Kikushige Y; Kunisaki Y; Kato K; Takenaka K; Akashi K; Miyamoto T
    Int J Hematol; 2022 Aug; 116(2):258-265. PubMed ID: 35524024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data.
    Mori Y; Jinnouchi F; Takenaka K; Aoki T; Kuriyama T; Kadowaki M; Odawara J; Ueno T; Kohno K; Harada T; Yoshimoto G; Takase K; Henzan H; Kato K; Ito Y; Kamimura T; Ohno Y; Ogawa R; Eto T; Nagafuji K; Akashi K; Miyamoto T
    Bone Marrow Transplant; 2021 Apr; 56(4):853-862. PubMed ID: 33139867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-Life Data on the Efficacy and Safety of Letermovir for Primary Prophylaxis of Cytomegalovirus in Allogeneic Hematopoietic Stem Cell Recipients: A Single-Center Analysis.
    Włodarczyk M; Wieczorkiewicz-Kabut A; Białas K; Koclęga A; Noster I; Zielińska P; Helbig G
    Turk J Haematol; 2024 Mar; 41(1):9-15. PubMed ID: 38345092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
    Jung S; Michel M; Stamminger T; Michel D
    BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factor analysis for cytomegalovirus reactivation under prophylaxis with letermovir after allogeneic hematopoietic stem cell transplantation.
    Mizuno K; Sakurai M; Kato J; Yamaguchi K; Abe R; Koda Y; Kataoka K; Mori T
    Transpl Infect Dis; 2022 Dec; 24(6):e13904. PubMed ID: 35870130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letermovir Prophylaxis for Cytomegalovirus Infection in Children After Hematopoietic Cell Transplantation.
    Richert-Przygonska M; Jaremek K; Debski R; Konieczek J; Lecka M; Dziedzic M; Bogiel T; Styczynski J; Czyzewski K
    Anticancer Res; 2022 Jul; 42(7):3607-3612. PubMed ID: 35790275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: Single center Canadian data.
    Pang I; Chen P; Trinh GV; Remberger M; Novitzky-Basso I; Gerbitz A; Kim DD; Kumar R; Lam W; Law AD; Lipton JH; Viswabandya A; Pasic I; Mattsson J; Michelis FV
    Eur J Haematol; 2024 Feb; 112(2):301-309. PubMed ID: 37830403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation under 100-Day Letermovir Prophylaxis: A Real-World 1-Year Follow-Up Study.
    Nho D; Lee R; Cho SY; Lee DG; Kim EJ; Park S; Lee SE; Cho BS; Kim YJ; Lee S; Kim HJ
    Viruses; 2023 Sep; 15(9):. PubMed ID: 37766290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Features of cytomegalovirus DNAemia and virus-specific T-cell responses in allogeneic hematopoietic stem-cell transplant recipients during prophylaxis with letermovir.
    Giménez E; Guerreiro M; Torres I; Aguilar C; Albert E; Hernández-Boluda JC; Hernani R; Pérez A; Amat P; Piñana JL; Montoro J; Solano C; Navarro D
    Transpl Infect Dis; 2023 Apr; 25(2):e14021. PubMed ID: 36748748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era.
    Sassine J; Khawaja F; Shigle TL; Handy V; Foolad F; Aitken SL; Jiang Y; Champlin R; Shpall E; Rezvani K; Ariza-Heredia EJ; Chemaly RF
    Clin Infect Dis; 2021 Oct; 73(8):1346-1354. PubMed ID: 33830182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.
    Lin A; Maloy M; Su Y; Bhatt V; DeRespiris L; Griffin M; Lau C; Proli A; Barker J; Shaffer B; Giralt SA; Jakubowski AA; Papadopoulos EB; Papanicolaou GA; Seo SK; Perales MA
    Transpl Infect Dis; 2019 Dec; 21(6):e13187. PubMed ID: 31585500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunovirology of cytomegalovirus infection in allogeneic stem cell transplant recipients undergoing prophylaxis with letermovir: A narrative review.
    Solano C; Giménez E; Albert E; Piñana JL; Navarro D
    J Med Virol; 2023 Aug; 95(8):e29005. PubMed ID: 37526411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro assessment of the combined effect of letermovir and sirolimus on cytomegalovirus replication.
    Giménez E; Guerreiro M; Gozalbo-Rovira R; Aguilar C; Albert E; Piñana JL; Solano C; Navarro D
    Rev Esp Quimioter; 2023 Oct; 36(5):526-530. PubMed ID: 37365797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended duration letermovir in allogeneic hematopoietic stem cell transplant.
    Hinman B; Cox J; Umoru G; Kamble R; Musick W
    Transpl Immunol; 2023 Dec; 81():101936. PubMed ID: 37770000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high-risk hematopoietic cell transplant recipients.
    Royston L; Royston E; Masouridi-Levrat S; Chalandon Y; Van Delden C; Neofytos D
    Immun Inflamm Dis; 2021 Sep; 9(3):771-776. PubMed ID: 33949798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
    Anderson A; Raja M; Vazquez N; Morris M; Komanduri K; Camargo J
    Clin Transplant; 2020 Jul; 34(7):e13866. PubMed ID: 32242979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of letermovir prophylaxis in CMV reactivation and disease after allogenic hematopoietic cell transplantation: a real-world, observational study.
    Brusosa M; Ruiz S; Monge I; Solano MT; Rosiñol L; Esteve J; Carreras E; Marcos MÁ; Riu G; Carcelero E; Martinez C; Fernández-Avilés F; Rovira M; Suárez-Lledó M; Salas MQ
    Ann Hematol; 2024 Feb; 103(2):609-621. PubMed ID: 37957371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical analysis of the usefulness of letermovir for prevention of cytomegalovirus infection after haploidentical hematopoietic stem cell transplantation].
    Ma R; He Y; Wang HF; Bai L; Han W; Cheng YF; Liu KY; Xu LP; Zhang XH; Wang Y; Zhang YY; Wang FR; Mo XD; Yan CH; Huang XJ; Sun YQ
    Zhonghua Nei Ke Za Zhi; 2023 Jul; 62(7):826-832. PubMed ID: 37394853
    [No Abstract]   [Full Text] [Related]  

  • 20. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
    Marty FM; Ljungman P; Chemaly RF; Maertens J; Dadwal SS; Duarte RF; Haider S; Ullmann AJ; Katayama Y; Brown J; Mullane KM; Boeckh M; Blumberg EA; Einsele H; Snydman DR; Kanda Y; DiNubile MJ; Teal VL; Wan H; Murata Y; Kartsonis NA; Leavitt RY; Badshah C
    N Engl J Med; 2017 Dec; 377(25):2433-2444. PubMed ID: 29211658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.